Abstract

Previous studies evaluating the associations of circulating Zn and Se levels with asthma have produced inconsistent results. Therefore, we conducted a meta-analysis to summarize and quantitatively synthesize the evidence from observational research. Meta-analysis. We searched PubMed, Web of Science and Scopus databases up to May 2019 for relevant available articles. Random-effects model was adopted to estimate the pooled standardized mean difference (SMD) with 95 % CI. Meta-regression analysis and 'leave-one-out' sensitivity analysis were used to assess heterogeneity. The meta-analysis focused on general populations. A total of twenty-six studies for Zn and forty studies for Se were included in the meta-analysis. The overall analyses identified that asthma patients had lower Zn (SMD = -0·40; 95 % CI -0·77, -0·03; I2 = 94·1 %) and Se (SMD = -0·32; 95 % CI -0·48, -0·17; I2 = 90·9 %) levels in serum or plasma compared with healthy controls. After removing the studies that contributed to the heterogeneity, the pooled SMD were -0·26 (95 % CI -0·40, -0·13; I2 = 37·42 %) for Zn and -0·06 (95 % CI -0·13, 0·02; I2 = 43·54 %) for Se. Lower circulating Zn and Se levels might be associated with an increased risk of asthma.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call